TESARO (TSRO) Misses Q1 EPS by 18c, Completes Enrollment in Phase 3 NOVA Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to TESARO (TSRO) Misses Q1 EPS by 18c, Completes Enrollment in Phase 3 NOVA Trial
April 30, 2015 4:02 PM EDT
Both the non-germline and germline BRCA mutation cohorts within NOVA are fully enrolled
Phase 3 data from NOVA is expected in Q4 2015
Patients are now being treated within the QUADRA trial
WALTHAM, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today provided an update on its niraparib clinical development program. The targeted enrollment has been achieved in both patient cohorts of the Phase 3 NOVA trial of niraparib, and TESARO expects data from NOVA in the fourth quarter of 2015. In addition, the QUADRA... More
April 30, 2015 4:01 PM EDT
Target enrollment completed for both cohorts of the niraparib Phase 3 NOVA trial; data expected in Q4 2015
QUADRA trial of niraparib initiated; initial data anticipated in early 2016
U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015
Cash and cash equivalents totaled approximately $399 million as of March 31, 2015
WALTHAM, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq: TSRO), an oncology-focused biopharmaceutical company, today reported operating results for first-quarter 2015 and provided an update on the Company's development programs.
"During the first quarter,... More
